BioSpace News Archive

Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced participation in a series of 1x1 meetings with institutional investors at the 10th Annual SV Leerink Global Healthcare Conference, occurring February 24 – 26, 2021.

Collaboration with Cleveland Clinic to support creation of novel next-generation mini-gene platform to pursue monogenic diseases not addressable by conventional AAV gene therapy technologies Collaboration with UT Southwestern Gene Therapy Program to develop new constructs incorporating novel mini-gene payloads, aligned with previously established partnership with Taysha

- US$100 million in milestone payments including US$20 million upfront, as well as a double-digit royalty - Nuance’s business model, commercial acumen and collaborative approach considered an ideal fit for Antibe

- Apollomics licenses worldwide rights (ex-China, Hong Kong and Taiwan) to develop and commercialize EO1001 - - EO1001 is an irreversible, pan-erbB inhibitor of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) -

Telehealth alliance with HelloMD increases patient access to cannabinoid formulations, providing quick and convenient access to consultations with licensed healthcare practitioners

Heat Biologics today reported positive interim data of the Company’s fully-enrolled Phase 2 trial of HS-110, in combination with Bristol-Myers Squibb’s (BMS) OPDIVO® (nivolumab) in advanced non-small cell lung cancer

To Support New Product Development of Custom Skin Fixation and Topical Solutions for Wound Care, Wearable Medical Devices and Healthcare Consumer Markets

MedAvail, Inc., a technology-enabled retail pharmacy company driving best in class medication adherence by embedding its pharmacy services directly into Medicare-focused clinics using its proprietary MedCenter solution, announced that it is partnering with Cigna Medical Group to provide patients an additional safe and convenient way to receive medications through MedAvail’s SpotRx pharmacy kiosks.

Minimally Invasive creates a new product category in breast aesthetics with a total addressable market of $4-5 billion

Feb. 9, 2021 13:08 UTC GOLDEN, Colo.--( BUSINESS WIRE )-- PharmaJet ® , the maker of innovative, needle-free injection technology, today announced that Marian Wentworth has been appointed to its Board of Directors. Ms. Wentworth, President and CEO of Management Sciences for Health, is an accomplished global health executive with extensive experience in global strategy, innovation, and development. Ron Lowy, Executive Chairman, PharmaJet Inc. said, “We are very pleased to we